Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)

被引：8
|
作者：
Tsurutani, J. [1 ]
Jacot, W. [2 ]
Yamashita, T. [3 ]
Riaz, F. [4 ]
Yerushalmi, R. [5 ]
Im, S-A. [6 ]
Niikura, N. [7 ]
Halser-Strub, U. [8 ]
Cortes, J. [9 ,10 ]
Wennstig, A-K. [11 ]
Chae, Y. [12 ]
Wang, X. [13 ]
Li, W. [14 ]
Simon, H. [15 ]
Masci, G. [16 ]
Tamburini, E. [17 ]
Aguilar, C. Orbegoso [18 ]
Tecson, K. [19 ]
Yung, L. [20 ]
Modi, S. [21 ]
机构：
[1] Showa Univ Hosp, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Inst Canc Montpellier, Med Oncol, Montpellier, France
[3] Kanagawa Canc Ctr, Breast Surg & Oncol, Yokohama, Kanagawa, Japan
[4] Stanford Sch Med, Med Oncol, Stanford, CA USA
[5] Tel Aviv Univ, Inst Oncol, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Tokai Univ, Breast Oncol, Sch Med, Isehara, Kanagawa, Japan
[8] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland
[9] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Madrid, Spain
[10] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Barcelona, Spain
[11] Sundsvall Hosp, Oncol, Sundsvall, Sweden
[12] Kyungpook Natl Univ, Med Oncol, Chilgok Hosp, Daegu, South Korea
[13] Zhejiang Canc Hosp, Med Oncol, Canc Res Inst, Hangzhou, Peoples R China
[14] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China
[15] CHU Brest, Oncol, Hop Morvan, Inst Cancerol & Hematol, Brest, France
[16] Humanitas Clin Res Hosp Rozzano, Med Oncol, Rozzano, MI, Italy
[17] Pia Fdn Cardinale G Panico Hosp, Oncol & Palliat Care, Tricase, Italy
[18] Daiichi Sankyo France SAS, Global Oncol R&D, Rueil Malmaison, France
[19] Daiichi Sankyo Inc, Evidence Generat, Basking Ridge, NJ USA
[20] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA
[21] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388P
引用
收藏
页码：S342 / S343
页数：2
相关论文
共 50 条
  • [41] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] FEASIBILITY ASSESSMENT OF AN INDIRECT TREATMENT COMPARISON (ITC) OF SACITUZUMAB GOVITECAN (SG) VS TRASTUZUMAB DERUXTECAN (T-DXD) IN HR+/HER2-METASTATIC BREAST CANCER (MBC)
    Shah, A.
    Thaliffdeen, R.
    Proudman, D.
    Verret, W.
    Sjekloca, N.
    Campone, M.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [43] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
    Hurvitz, S. A.
    Kim, S. -B.
    Chung, W. -P.
    Im, S. -A.
    Park, Y. H.
    Hegg, R.
    Kim, M. -H.
    Tseng, L. -M.
    Petry, V.
    Chung, C. -F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Egorov, A.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Tecson, K.
    Verma, S.
    Cortes, J.
    ESMO OPEN, 2024, 9 (05)
  • [44] ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
    Meng, Y.
    Mu, Y.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S402 - S402
  • [45] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Trastuzumab deruxtecan vs T-DM1 in HER2+mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
    Im, Seock-Ah
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Lee, Caleb
    Nishijima, Soichiro
    Hamada, Kyohei
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S465
  • [47] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
    Tolaney, S. M.
    Barroso-Sousa, R.
    Jiang, Z.
    Park, Y. H.
    Rimawi, M.
    Manich, C. Saura
    Schneeweiss, A.
    Toi, M.
    Yu, T.
    Shetty, J.
    Herbolsheimer, P.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S507 - S508
  • [48] Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
    Dieras, Veronique
    Deluche, Elise
    Lusque, Amelie
    Pistilli, Barbara
    Bachelot, Thomas
    Pierga, Jean-Yves
    Viret, Frederic
    Levy, Christelle
    Salabert, Laura
    Le Du, Fanny
    Dalenc, Florence
    Jouannaud, Christelle
    Venat-Bouvet, Laurence
    Jacquin, Jean-Philippe
    Durando, Xavier
    Petit, Thierry
    Oukhatar, Celine Mahier -Ait
    Filleron, Thomas
    Mosele, Maria Fernanda
    Lacroix-Triki, Magali
    Ducoulombier, Agnes
    Andre, Fabrice
    CANCER RESEARCH, 2022, 82 (04)
  • [49] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh
    Siena, Salvatore
    Takashima, Atsuo
    Kato, Takeshi
    Van den Eynde, Marc
    Di Bartolomeo, Maria
    Komatsu, Yoshito
    Kawakami, Hisato
    Peeters, Marc
    Andre, Thierry
    Lonardi, Sara
    Yamaguchi, Kensei
    Tie, Jeanne
    Castro, Cristina Gravalos
    Strickler, John H.
    Barrios, Daniel
    Yan, Qi
    Kamio, Takahiro
    Kobayashi, Kojiro
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345